Pentasaccharides. The new anticoagulants

Area of Science:

• Pharmacology
• Hematology
• Clinical Medicine

Background:

• Venous thromboembolism (VTE) is a prevalent and preventable condition.
• Recent advancements have improved VTE treatment and prophylaxis strategies.
• Low molecular weight heparins (LMWH) are standard for deep venous thrombosis (DVT) and pulmonary embolism (PE) treatment.

Purpose of the Study:

• To review the efficacy and safety of fondaparinux, a synthetic pentasaccharide, in VTE prophylaxis and treatment.
• To highlight the advantages of pentasaccharides over existing anticoagulant therapies.
• To discuss the role of fondaparinux in orthopedic surgery, abdominal surgery, high-risk medical patients, and active DVT/PE treatment.

Main Methods:

• Review of clinical investigations and data on fondaparinux use.
• Comparison of fondaparinux with unfractionated heparin (UFH) and LMWH in VTE management.
• Analysis of safety profiles, including side effects like thrombocytopenia.

Main Results:

• Fondaparinux demonstrated superior efficacy to LMWH in VTE prophylaxis for orthopedic procedures.
• Pentasaccharides showed comparable safety and efficacy to UFH and LMWH in treating DVT and PE.
• Fondaparinux offers convenience through once-daily injections and no requirement for monitoring.

Conclusions:

• Fondaparinux and other pentasaccharides represent a significant advancement in anticoagulation therapy.
• Their favorable efficacy, safety profile, and convenience position them as leading future anticoagulant options.
• Pentasaccharides are effective for both VTE prophylaxis and treatment across various patient populations.